Author Interviews, Diabetes, Kidney Disease, NYU, Weight Research / 20.10.2025
NYU Study Finds GLP-1 Medications Associated with Clinically Meaningful Benefit in Dialysis Patients
MedicalResearch.com Interview with:
Michael A. Weintraub, MD
Clinical Assistant Professor
Department of Medicine
NYU Grossman School of Medicine
MedicalResearch.com: What is the background for this study?
Response: The study addresses a critical knowledge gap in diabetes
management for dialysis patients.
Of the 808,000 people on dialysis in the United States,
approximately 60% have diabetes and would be
eligible for GLP-1 receptor agonists (GLP-1 RAs).
However, these medications have not been well-studied in this population because
dialysis dependence is frequently an exclusion criterion in clinical
trials.
(more…)
Response: Cigarette smoking is one of the well-established causes of periodontitis, but the effect of using electronic cigarettes (e-cig), especially its long-term impact on periodontal health, is not yet clearly understood. Considering the increased popularity of e-cig use, especially among teenagers and young adults, and the known effect of high nicotine concentration in e-cigarette products, we conducted this clinical research to see if there were differences in periodontal health between e-cig users, traditional smokers, and nonsmokers. The study consisted of two visits, 6 months apart, where measures of oral and periodontal health were obtained.
Our data showed significantly greater clinical attachment loss in the e-cigarette users and cigarette smokers than in the non-smokers at both study visits. In only e-cigarette users, we observed an over 0.2 mm average increase in the clinical attachment loss after 6 months.
Ruth Fernandez-Ruiz, MD
Post-Doctoral Fellow
Department of Rheumatology
NYU Langone Heath
MedicalResearch.com: What is the background for this study?
Response: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for COVID-19 with biologic, genetic, demographic, clinical and treatment issues at play. By the nature of their chronic inflammatory autoimmune condition, the presence of comorbidities, and regular use of immunosuppressants, these individuals would traditionally be considered at high risk of contracting SARS-CoV-2 and possibly having worse outcomes from the viral infection.
However, it might be speculated that inherently elevated type I Interferon, characteristic of the majority of patients with SLE, confers a protective effect as a first line anti-viral defense. Additionally, hydroxychloroquine, which was suggested as a potential therapeutic agent for COVID-19 early on, is used in most patients with SLE. Accordingly, we initiated this study to provide critical data needed to address the frequency and severity of COVID-19 in patients with SLE.